Kadish, J.L., Choi C.C., Czop J.K.; "Phagocytosis of unopsonized zymosan particles by trypsin-sensitive and beta-glucan-inhibitable receptors on bone marrow-derived murine macrophages," Immunol Res 5: 129-138. 1986. *
Kan V.L., Bennett J.E.; "Beta 1, 4-oligoglucosides inhibit the binding of Aspergillus fumigatus conidia to human monocytes," J Infect Dis 163: 1154-1156. 1991.
Kaplan J.; "Acceleration of Wound Healing by a Live Yeast Cell Derivative". Archives and Surgery", Sep. 1984; 119:1005-1008. 1984.
Kapteyn J.C., Montijn R.C., et al; "Retention of Saccharomyces cerevisiae cell wall proteins through a phosphodiester-linked beta-1, 3/beta-1, 6-glucan heteropolymer," Glycobiology 6: 337-345. 1996. * Institute of Molecular Cell Biology, U of Amsterdam, The Netherlands.
Kapteyn J.C., Montijn R.C., et al; "Covalent association of beta-1, 3-glucan with beta-1, 6-glucosylated mannoprotein in cell walls of Candida albicans," J Bacteriol 177: 3788-3792. 1995. *
Kapteyn J.C., Montijn R.C., et al; "Glucosylation of cell wall proteins in regenerating spheroplasts of Candida albicans," FEMS Microbiol Letter 128: 271-277. 1995. *
Kapteyn J.C., Montijn R.C., et al; "Identification of beta-1, 6-glucosylated cell wall proteins in yeast and hyphal forms of Candida albicans," Euro J Cell Biol 65: 402-407. 1994. *
Kasahara S., Ben Inoue S., Mio T., Yamada T., Nakajima T., Ichishima E., Furuichi Y., Yamada H., "Involvement of cell wall beta (1-3) glucan-glucan in the action of HM-1 killer toxin", FEBS Lett 348 (1): 27-32. 1994.
Kasai, S., Fujimoto S., Nitta K., Baba H., Kunimoto T., "Antitumor activity of polymorphonuclear leukocytes activated by a B-1, 3-D-glucan". J. Pharmacobiodyn. 14:519-525. Medline.
Kashkina Ma., Freidlin IS., "Macrophage activation by polysaccharides from yeast-like fungi", Biull Eskp Biol. Med 89 (4): 439-441. 1980.
Kay J., Czop J.K., ""Enhancement of human monocyte beta-glucan receptors by glucocorticoids," Immunology 81: 96-102. 1994. *
Kimura, et aL., "In Vitro Activation of Human Adherent Cells by a Glucan, Schizophyllan". J. Reticuloendothel.; Soc. 34: 1-11. 1983.
Kohl, et al., "Inhibition of Human Monocyte-Macrophage and Lymphocyte Cytotoxicity to Herpes simplex Cells by Glucan". J. Immunol. Methods; 29: 361-368. 1979. * Quote: "Particulate, cell-associated glucan irreversibly inhibited MP antibody-dependent cellular cytotoxicity (ADCC)."
Kokoshis P.L., Williams D.L., Cook J.A., Di Luzio N.R.; Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan. Science 199: 1340-1342, 1978. * Quote: "These studies indicate that glucan confers an enhanced state of host defense against bacterial infections."
Konopski Z., Seljelid R., Eskeland T.; "Interferon-gamma inhibits endocytosis of soluble animated beta-1, 3-D-glucan and neutral red in mouse peritoneal macrophages," J Interferon Cytokine Res 15(7): 597-603. Jul 1995. * Dept of Exper Path and Anat, U of Tromso, Norway.
Konopski Z., Seljelid R., Eskeland T.; "IFN-gamma inhibits internalization of soluble aminated beta-1-3-D-glucan by macrophages and thereby down-regulates the glucan induced release of TNF-alpha and IL-1 beta," Scand J. Immunol 40: 57-63. 1994. *
Konopski Z., Seljelid R., Eskeland T.; "A novel immunomodulator soluble aminated beta-1, 3-D-glucan: binding characteristics to mouse peritoneal macrophages," Biochem Biophys Acta 1221(1): 61-65. Mar 1994. *
Konopski Z., Seljelid R., Eskeland T.; "Cytokines and PGE2 modulate the phagocytic function of the beta-glucan receptor in macrophages," Scand J. Immunol 37: 587-592. 1993. *
Konopski, Z., et al., "Phagocytosis of beta-1, 3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," Scand. J. Immunol.; 33:297-306. 1991. *
Kopecka M.; "Electron microscopic study of purified polysaccharide components glucans and mannan of the cell walls in the yeast Saccharomyces cerevisiae," J Basic Microbiol 25: 161-174. 1985. *
Lahnborg G., Hedstrom K.G., Nord C.E.; "The Effect of Glucan - A Host Resistance Activator and Ampicillin on Experimental Intraabdominal Sepsis". Journal of Reticuloendothelial Society. 32: 347-353. 1982. * Quote: "It is concluded that glucan, in combination with Ampicillin, has a significant effect on the survival rate of rats with induced peritonitis, probably by enhancing the activities of the reticuloendothelial system, an important part of the total host resistance."
Lahnborg, et al., "Glucan-Induced Enhancement of Host Resistance in Experimental Intraabdominal Sepsis". Eur. Surg. Res.; 401-408. 1982. *
Larm O., Seljelid R., "Water-soluble aminated beta-1, 3-bount D-glucan and composition containing same," U.S. Patent 4707471; Issued Nov 17, 1987.
Leibovich S.J., et al., "Promotion of Wound Repair in Mice by Application of Glucan". J. Reticuloendothel, Soc. 27: 1-11. 1980.
Lejeune FJ., Vercammen-Granfjean A., Mendes Da Costa P., Bron D., Defleur V., "Suppressor cell induction and reticuloendothelial cells activation produced in the mouse by beta(1-3)glucan 1-3 glucan", Adv. Exp. Med. Biol. 121 (A): 235-244. 1979. *
Lotzova and Gutterman, "Effect of Glucan on Natural Killer (NK) Cells: Further Comparison between NK Cell and Bone Marrow Effector Cell Activities". J. Immunol., 123: 607-611. 1979.
Mahauthaman R, Howell CJ, Spur BW, Youlten LJ, Clark TJ, Lessof MH and Lee TH; "The generation and cellular distribution of leukotriene C4 in human eosinophils stimulated by unopsonized zymosan and glucan particles;" J Allergy Clin Immunol 81:696. 1988.
Manners, D.J., Masson, A.J. & Patterson, J.C.: "Heterogeneity of Glucan Preparations from the Walls of Various Yeasts". J. of Gen Micro.; 411-417. 1974.
Manners, D.J., et al., "The Structure of a beta- (1.fwdarw.3)-D-Glucan from Yeast Cell Walls," BiochemJ.; 135: 19-30. 1973.
Mansell P.W.A., Rowden G., Hammer C.; Clinical experiences with the use of glucan. Chirigos MA, ed.; Immune Modulation and Control of Neoplasia by Adjuvant Therapy. Raven Press, New York 255-280; 1978.
Mansell P.W.A., et al., Activation of the Alternative Complement Pathway by Water-Insoluble Glucans of Streptococcus mutans: the Relation Between Their Chemical Structures and Activating Potencies". Macrophage-Mediated Destruction of Human Malignant Cells in Vitro; Inai et al., J. Immunol (1976); 1256-1260. 1976
Mansell P.W.A., Ichinose H., Reed R.J., Krements E.T., McNamee R.B., Di Luzio N.R.; "Macrophage-mediated Destruction of Human Malignant Cells in Vitro". Journal of National Cancer Institute; 54: 571-580. 1975. Quote: "The initial 9 patients studied had malignant carcinoma of the breast. Control and experimental lesions were injected; subsequently biopsies were performed at varying intervals for histologic evaluation. Always when glucan or glucan and RF fractions were administered intra-lesionally; the size of the lesion was strikingly reduced in as short a period as 5 days. ...In small lesions, resolution was complete, whereas in large lesions, resolutions was partial."
Marchetti M., Pisani S., Pietropaolo V., Seganti L., Nicoletti R., Degener A., Orsi N., "Antiviral effect of a polysaccharide from Sclerotium glucanicum towards herpes simplex virus type 1 infection", Planta. Med. 62 (4): 303-307. 1996.
Mashiba, et Al., "In Vitro Activation of Human Adherent Cells by a Glucan Schlzophillan". Japan J. Exp. Med; 53: 195-198. 1983.
Meira, D.A., et al; The Use of Glucan as Immunostimulant in the Treatment of Paracoccidioidomycosis; Am J. Trop Med Hyg 55(5), 496-503; 1996. Dept of Trop Dis, Dept of Microbio, State U of Sao Paulo, Brazil. Quote: "...glucan enhances the immune response through stimulation of macrophages by increasing their number, size, and function, stimulates secretion of lysozyme and TNF by activated macrophages, increases the phagocytosis of antigens, activates the formation of granulocyte and monocyte colonies, and factors increased activity of T and B lymphocytes, as well as complement activation. "
Mitsutake K, et al; "Enolase Antigen, Mannan Antigen, Cand-Tec Antigen, and (-Glucan in Patients with Candidemia," J of Clin MicroB, p1918-1921, 1137; 1996. Copyrighted. Sec Dept of Int Med, Nagasaki U Sch of Med, Nagasaki, Japan. *
Miura N.N., Ohno N., Adachi Y., Yadomae T.; "Characterization of sodium hypochlorite degradation of Beta-glucan in relation to its metabolism in vivo," Chem Pharm Bulletin (Tokyo) 44: 2137-2141. 1996. *
Miyazaki, T., et al., "Structural Examination of Antitumor, Water-Soluble Glucans from Grifora umbrellata by Use of Four Types of Glucanase," Carbohydrate Research; 65:235-243. 1978.
Modification of Experimental Viral Hepatitis by Glucan Induced Macrophage Activation". Elesevier/North Holland Biomedical Press; pp. 363-368. 1980.
Morikawa K., Takeda, M., Yamazaki, M., and Mizuno D., "Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear B-1, 3-D-glucan and other immunomodulators in murine cells". Cancer Res., 45: 1496-1501. (Medline).
Montijn RC et al, "Glucomannoproteins in the cell wall of Saccharomyces cerevisiae contain a novel type of carbohydrate side chain," J Biol Chem, 269(30): 19338-19342: Inst of Molecular C Biol, U of Amsterdam, The Netherlands. Jul 1994.
Mortimer RK, Contopoulou CR, King JS, "Genetic and physical maps of Saccharomyces cerevisiae," Edition 11. Yeast 8:817-902. 1992.
Muller A., Rice P.J., Ensley H.E., et al; "Receptor binding and internalization of a water-soluble (1-->3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines," J.Immunol 156: 3418-3425. 1996. *
Murphy, "The DNA sequence of the gene and genetic control sites for the execration B. subtilis enzyme beta-glucanase," Nucleic Acids Res.; 12:5355-5367. 1984.
Nemoto J., Ohno N., et al; Analysis of cytokine in mBNAs induced by the administration of a highly branched (1-3)-B-D-glucan. OL-2. Biol. Pharm Bull. 17:948-54; 1994.
Niki L., Allbright L., "Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish." (A method to stimulate the immune system by a beta (1-3) glucan having a beta (1-3) glucan-1, 3-linked main chain with beta (1-3) glucan-1, 6-linked single glucose side chains); U.S. Patent 5189028. Issued February 23, 1993.
Niskanen E.O., Burgaleta C., Cline M.J., Goide D.W.; Effect of glucan, a macrophage activator, on murine haemopoietic cell proliferation in diffusion chambers in mice; Cancer Res 38: 1406-1409, 1978.
Norton MD, JA [Prof. of Surg, Chief of Endocrine and Oncologic Surgery]; "Editorial: Annals of Surgery," Washington University School of Medicine, Nov 1994. Quote: "In a prospective, randomized double-blind study, [Babineau, et.al.] demonstrate that the preoperative administration of PGG-glucan, a substance derived from yeast that increases the microbial killing activity of leukocytes, can decrease infectious complications in patients undergoing major surgical procedures...the preliminary results are positive and should be interpreted as good news."
Nuyen and Stadtsbaeder, "Comparative Biological and Antitoxoplasmic Effects of Polysaccharides, In Vitro". In Advances in Exper. Med. and Biology, vol. 121A Escobar and Friedman, eds. Plenum Press, New York; pp. 255-266. 1980.
Ohno N., Terui T., Chiba N., Kurachi K., Adachi Y., Yadomae T.; "Resistance of highly branched (1-->3)-beta-D-glucans to
formolysis," Chem Pharm Bulletin (Tokyo) 43: 1057-1060. 1995. *
Olson E.J., Standing J.E, et al; "Fungal beta-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages," Infect Immun 64: 3548-3554. 1996.
Onderdonk, AB., et al., "Anti-Infective Effect of Poly-.beta.1-6 -Glucotrisyl-beta 1-3-Glucopyranose Glucan In Vivo,"
Infec. Immun.; 60:1642-1647. 1992. Dept of Pathology, Channing Lab, Brigham and Women's Hospital, Boston, MA. * Quote: "Mice challenged with Escherichia coli or Staphylococcus aureus were protected against lethal peritonitis by the intravenous administration of 10 micrograms of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose
(PGG) glucan per animal 4 to 6 h prior to bacterial challenge."
Ostroff, G.R.; "Inhibition of infection-stimulated oral tissue destruction by beta (1-3) glucan (1,3)-glucan," U.S. Patent 5622940. Issued April 22, 1997.>
Ostroff, et al., "Manipulation of Yeast Glucan Structure: Molecular Weight, Branch Frequency and Branch Length". The
Fermentor, 9(12)L51, American Cancer Society; Abstract No. 19.; Aug 1989.
Patchen M.L., D'Alesandro M.M., Brook I., Blakely W.F. Mcvittie T.J.; "Glucan: Mechanisms Involved in Its
'Radioprotective' Effect". J Leuc Biol.; 42:95-105. 1987.
Pachen M.L. Macvittie TJ, "Comparative effects of soluble and particulate glucans on survival in irradiated mice," J Biol Response Mod 5(1): 45-60. Feb 1986. * Experimental Hematology Dept, Armed Forces Radiobiology Research Inst, Bethesda, MD. Quote: "Both glucan-P and glucan-F enhanced the recovery of peripheral blood white cell numbers, platelet numbers, and hematocrit values. In addition, both agents increased endogenous pluripotent hemopoietic stem cell numbers in sublethally irradiated mice."
Pachen M.L., Macvittie T.J.; "Stimulated Hemopeiesis and Enhanced Survival Following Glucan Treatment in Sublethally and Lethally Irradiated Mice". Int. J.
Immunopharmac; 7: 923-932. 1985.
Patchen M.L., et al., J. Biol. Res. Mod.; 3:627-633. 1984. Patchen
M.L., McVittie T.J.; Temporal Response of Murine Pluripotent Stem Cells and Myeloid and Erythroid Progenitor Cells to Low-dose Glucan Treatment. Acta
Hemat; 70:281-288. 1983. Experimental Hematology Dept, Armed Forces Radiobiology Research
Insti, Bethesda, MD. * Quote: "Clearly, there are numerous possible uses for an agent such as glucan, which is a potent stimulator of hemopoietic activity. Currently, we [U.S. Armed Services] are using glucan to enhance hemopoietic proliferation in conjunction with hemopoietic injury induced by radiation."
Patchen, M.L., Lotzova E.; Modulation of murine hemopoiesis by glucan; Exp Hermatol 8: 409-422, 1980.
Patent Abstracts of Japan; "Production of beta-1, 3-glucan" (24 May 1989) vol. 13, No. 224, (C-599) {3572) & Japanese Patent Application No. 137297; 7 Feb. 1989.
Patent Abstracts of Japan; "Production of beta-1, 3-glucan by cell of genus Euglena," 15 Aug 1988, vol. 12, No. 299, (C-520) {3146} & Japanese Patent Application No. 6371192, 31 Mar. 1988.
Paulik S., Svrcek S., et al; "The effect of fungal and yeast glucan and levamisole on the level of the cellular immune response in vivo and leukocyte phagocytic activity in mice," Vet Med
(Praha) 37: 675-685. 1992. *
Petre, et al., "Purification and properties of an endo-beta-1, 4-glucanase from Clostridium
thermocellum," (abst.) 7-Enzymes, (1981); 95:145879q, Biochemie; 63:629-639. 1981.
Popisil, et al., "Glucan Induced Hemopoietic Recovery in Gamma-Irradiated Mice".
Experientia; 38: 1232-1234. 1982.
Poutsiaka D.D., et al, "Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production," Blood 82: 3695-3700; 1993. Dept of Med, New England Med
Ctr, Boston, MA. Quote: "Because of their differential effects on cytokine production, beta-glucans may be used to therapeutic advantage in the diseases in which IL-1 is implicated."*
Proctor J.W., Stiteler R.D., Yamamura Y., Mansell P.W., Winters R.,
"Effect of glucan and other adjuvants on the clearance of radiolabeled tumor cells from mouse lungs", Cancer Treat. Rep. ^2 (11): 1873-1880. (1978).
Proctor and Yamamura; "Letters to the Editor: Effectiveness of Glucan in the Treatment of Human
Neoplasia". J. Nat'l Cancer Inst.; 61: 1179-1180. 1978.
|
